查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600897

移植HLA型检测市场：依产品与服务、技术、移植类型、应用、最终用户 - 2025-2030 年全球预测

HLA Typing for Transplant Market by Product & Service, Technology, Transplant Type, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，可移植HLA型检测市值为9.9831亿美元，预计到2024年将达到10.8639亿美元，复合年增长率为9.09%，预计到2030年将达到18.3658亿美元。

移植的HLA型检测是一项重要的医疗实践，可将器官或组织供体的人类白血球抗原 (HLA) 与受体的相匹配，确保相容性并降低排斥风险。这个过程对于肾臟、肝臟、心臟和骨髓移植等器官移植至关重要，其中准确的匹配极大地影响移植的成功和寿命。 HLA型检测市场主要是由全球器官衰竭发生率上升和器官移植需求增加所推动的。此外，技术进步，特别是分子诊断技术的进步，提高了HLA型检测的准确性和效率，促进了HLA型检测在医院和实验室的应用。关键的成长要素包括器官捐赠意识的提高、政府支持移植活动的倡议的增加以及导致器官衰竭的慢性疾病盛行率的增加。然而， HLA型检测成本高、器官可用性有限以及器官移植的伦理问题等挑战正在限制市场成长。然而，这个领域充满了机会，特别是随着次世代定序的进步和个人化医疗的传播。在自动化HLA型检测技术和高通量HLA型检测技术等领域进行创新的公司可能具有竞争优势。医疗保健基础设施迅速改善的新兴市场的扩张也为市场参与企业提供了利润丰厚的机会。儘管有这些潜在的好处，严格的法律规范和匹配流程的复杂性仍然是主要障碍。未来的研究预计将集中于优化具有成本效益的技术并加速 HLA 匹配，以提高可及性和效率。该市场的特点是对创新和技术进步的持续需求，这表明投资于研发并采用数位医疗解决方案的主要企业可能会获得市场占有率。

主要市场统计
基准年[2023] 99831万美元
预测年份 [2024] 1,086,390,000 美元
预测年份 [2030] 1,836.58 百万美元
复合年增长率（%） 9.09%

市场动态：快速发展的移植HLA型检测市场的关键市场洞察

可移植HLA型检测市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 骨髓、器官和血液移植过程的发生率增加
    • 在个人化医疗中采用HLA型检测以减少移植物排斥
  • 市场限制因素
    • 报销不足和保险政策不足
  • 市场机会
    • 移植诊断和HLA型检测方法领域的技术进步
    • 偏好免疫抑制治疗以补充HLA型检测
  • 市场挑战
    • 对HLA型检测不准确的担忧

波特五力：驾驭移植HLA型检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解移植HLA型检测市场的外部影响

外部宏观环境因素在塑造可移植HLA型检测市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解移植HLA型检测市场的竞争状况

移植HLA型检测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵植入HLA型检测市场供应商绩效评估

FPNV定位矩阵是评估可移植HLA型检测市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 骨髓、器官和血液移植手术的发生率上升
      • 在个人化医疗中采用HLA型检测来减少移植物排斥
    • 抑制因素
      • 缺乏承保范围和保险不足
    • 机会
      • 移植诊断和HLA型检测方法领域的技术进步
      • 优先考虑免疫抑制治疗以补充HLA型检测
    • 任务
      • 对HLA型检测不准确的担忧
  • 市场区隔分析
    • 技术：采用分子检测技术，特异性高、重现性佳
    • 产品和服务：优先考虑促进资料解释和实验室工作流程管理的软体和服务
    • 移植类型：越来越多使用干细胞移植疗法来治疗白血病、淋巴瘤、骨髓瘤和免疫系统疾病
    • 应用： HLA型检测在器官移植的诊断应用的应用
    • 最终用户：高度渗透到独立参考实验室，以实现高通量能力和扩充性。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章移植HLA型检测市场：依产品及服务分类

  • 装置
  • 试剂/耗材
  • 软体和服务

第七章 移植HLA型检测市场：依技术分类

  • 分子检测技术
    • 基于PCR的分子检测
      • 即时PCR
      • 序列特异性寡核苷酸PCR
      • 序列特异性引子PCR
    • 基于定序的分子测定
      • 次世代定序
      • 桑格序列
  • 非分子检测技术

第八章 依移植类型分類的HLA型检测市场

  • 器官移植
  • 干细胞移植
  • 组织移植

第 9 章 移植HLA型检测市场：依应用分类

  • 诊断应用
    • 抗体筛检
    • 嵌合状态监测
  • 调查申请

第 10 章 移植HLA型检测市场：依最终使用者分类

  • 临床实验室/调查机构
  • 医院及移植中心
  • 独立参考实验室

第十一章 美洲HLA型检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太移植HLA型检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲移植HLA型检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • GenDx 推出 NGS-Turbo：利用 Oxford Nanopore Technologies 的定序设备彻底改变高解析度HLA型检测
    • Omixon 推出单重人类白血球抗原扩增试剂套件NanoTYPE MONO 和 MONOall RUO，与 Oxford Nanopore 的 MinION 平台相容。
    • JURA Bio 宣布与 Replay 产品公司 Syena 合作，推进癌症 T 细胞受体 NK 疗法
    • Ossium Health 与 Be the Match 宣布合作，以提高骨髓移植的可近性和治疗效率
    • BriaCell接受NCI津贴开发癌症平台
    • Tempus 宣布与 TScan Therapeutics 开展伴同性诊断合作
    • Metropolis Healthcare 推出下一代 HLA 器官移植检测
    • CD Genomics Longseq 部门宣布人类白血球抗原 (HLA) 分型服务
    • Garuda Therapeutics 获得 6,200 万美元 B 轮资金筹措，以推进现成的血液干细胞技术平台
    • FDA 已授予HLA型检测测试 De Novo 分类，用作转移性或不可切除的葡萄膜黑色素瘤 T 细胞受体治疗的诊断辅助。
    • Eurobioscientific 以 1.323 亿美元收购 GenDx
    • Be The Match BioTherapies 与 Atara Biotherapeutics 延长多年伙伴关係协议

公司名单

  • Takara Bio Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • CapitalBio Technology Co., Ltd.
  • Pure MHC, LLC
  • Laboratory Corporation of America Holdings
  • TCR2 Therapeutics by Adaptimmune Therapeutics PLC
  • Bio-Techne Corporation
  • NeoGenomics Laboratories, Inc.
  • Oxford Nanopore Technologies PLC
  • Pure Protein, LLC
  • OraSure Technologies, Inc.
  • CareDx, Inc.
  • DiaSorin SpA
  • BAG Diagnostics GmbH
  • GenDx by Eurobio Scientific Group
  • TBG Diagnostics Ltd.
  • QIAGEN NV
  • HEALIOS KK
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Illumina, Inc.
  • BGI Genomics Co.,Ltd.
  • Becton, Dickinson, and Company
  • Hologic, Inc.
  • Bio-Rad Laboratories, Inc.
  • Lonza Group Ltd.
  • STEMCELL Technologies Inc.
  • F. Hoffman-La Roche AG
  • CeGaT GmbH
  • Fujirebio, Inc. by HU Group Holdings, Inc.
  • Eurofins Scientific SE
  • Invectys Inc.
  • Creative Biolabs, Inc.
  • ImmunOs Therapeutics AG
  • Immucor, Inc. by Werfen, SA
  • Immatics NV
  • T-Cure Bioscience Inc.
  • Agilent Technologies, Inc.
  • Garuda Therapeutics
Product Code: MRR-3D2FD205B873

The HLA Typing for Transplant Market was valued at USD 998.31 million in 2023, expected to reach USD 1,086.39 million in 2024, and is projected to grow at a CAGR of 9.09%, to USD 1,836.58 million by 2030.

HLA typing for transplant is a crucial procedure in medical science that involves matching the human leukocyte antigens (HLA) of organ and tissue donors with those of recipients to ensure compatibility and reduce the risk of rejection. This process is vital in organ transplantation, including kidney, liver, heart, and bone marrow transplants, where precise matching can significantly influence the success rate and longevity of the transplant. The market for HLA typing is primarily driven by the rising incidence of organ failure and the increasing demand for organ transplants globally. Additionally, advancements in technology, particularly in molecular diagnostics, have enhanced the precision and efficiency of HLA typing, propelling its application in both hospitals and research laboratories. Key growth influencers include the rising awareness about organ donation, increasing government initiatives supporting transplantation activities, and the growing prevalence of chronic diseases leading to organ failure. However, challenges such as the high cost of HLA typing procedures, limited availability of organs, and ethical concerns surrounding organ transplantation act as restraints to market growth. Nevertheless, opportunities abound in the sector, particularly with the advancements in next-generation sequencing and the scope for personalized medicine. Companies poised to innovate in fields like automated and high-throughput HLA typing technologies may gain a competitive edge. Expansions in emerging markets, where healthcare infrastructure is rapidly improving, also present lucrative opportunities for market players. Despite these potential gains, stringent regulatory frameworks and the complexity of matching processes remain significant hurdles. Future research could focus on optimizing cost-effective techniques and improving the speed of HLA matching to enhance accessibility and efficiency. The market is characterized by a continuous demand for innovation and technological advancements, suggesting that companies investing in R&D and adopting digital healthcare solutions will likely lead in capturing market share.

KEY MARKET STATISTICS
Base Year [2023] USD 998.31 million
Estimated Year [2024] USD 1,086.39 million
Forecast Year [2030] USD 1,836.58 million
CAGR (%) 9.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HLA Typing for Transplant Market

The HLA Typing for Transplant Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of bone marrow, organ, and blood transplant processes
    • Adoption of HLA typing in personalized medicine for reduced graft rejections
  • Market Restraints
    • Lack of reimbursement and inadequate insurance policies
  • Market Opportunities
    • Technological advancements in the field of transplant diagnostics and HLA-typing methods
    • Preference for immunosuppressive therapies to complement HLA typing
  • Market Challenges
    • Concerns regarding the inaccuracy of HLA typing

Porter's Five Forces: A Strategic Tool for Navigating the HLA Typing for Transplant Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HLA Typing for Transplant Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HLA Typing for Transplant Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HLA Typing for Transplant Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HLA Typing for Transplant Market

A detailed market share analysis in the HLA Typing for Transplant Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HLA Typing for Transplant Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HLA Typing for Transplant Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Chugai Pharmaceutical Co., Ltd., CapitalBio Technology Co., Ltd., Pure MHC, LLC, Laboratory Corporation of America Holdings, TCR2 Therapeutics by Adaptimmune Therapeutics PLC, Bio-Techne Corporation, NeoGenomics Laboratories, Inc., Oxford Nanopore Technologies PLC, Pure Protein, LLC, OraSure Technologies, Inc., CareDx, Inc., DiaSorin S.p.A., BAG Diagnostics GmbH, GenDx by Eurobio Scientific Group, TBG Diagnostics Ltd., QIAGEN N.V., HEALIOS K.K., Thermo Fisher Scientific, Inc., Merck KGaA, Illumina, Inc., BGI Genomics Co.,Ltd., Becton, Dickinson, and Company, Hologic, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., STEMCELL Technologies Inc., F. Hoffman-La Roche AG, CeGaT GmbH, Fujirebio, Inc. by H.U. Group Holdings, Inc., Eurofins Scientific SE, Invectys Inc., Creative Biolabs, Inc., ImmunOs Therapeutics AG, Immucor, Inc. by Werfen, S.A., Immatics N.V., T-Cure Bioscience Inc., Agilent Technologies, Inc., and Garuda Therapeutics.

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product & Service, market is studied across Instruments, Reagents & Consumables, and Software & Services.
  • Based on Technology, market is studied across Molecular Assay Technologies and Non-Molecular Assay Technologies. The Molecular Assay Technologies is further studied across PCR-Based Molecular Assays and Sequencing-Based Molecular Assays. The PCR-Based Molecular Assays is further studied across Real-Time PCR, Sequence-Specific Oligonucleotide-PCR, and Sequence-Specific Primer-PCR. The Sequencing-Based Molecular Assays is further studied across Next-Generation Sequencing and Sanger Sequencing.
  • Based on Transplant Type, market is studied across Organ Transplantation, Stem Cell Transplantation, and Tissue Transplantation.
  • Based on Application, market is studied across Diagnostic Applications and Research Applications. The Diagnostic Applications is further studied across Antibody Screening and Chimerism Monitoring.
  • Based on End-User, market is studied across Clinical Laboratories & Research Institution, Hospitals & Transplant Centers, and Independent Reference Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
      • 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of reimbursement and inadequate insurance policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
      • 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
    • 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
    • 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
    • 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
    • 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HLA Typing for Transplant Market, by Product & Service

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables
  • 6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

  • 7.1. Introduction
  • 7.2. Molecular Assay Technologies
    • 7.2.1. PCR-Based Molecular Assays
      • 7.2.1.1. Real-Time PCR
      • 7.2.1.2. Sequence-Specific Oligonucleotide-PCR
      • 7.2.1.3. Sequence-Specific Primer-PCR
    • 7.2.2. Sequencing-Based Molecular Assays
      • 7.2.2.1. Next-Generation Sequencing
      • 7.2.2.2. Sanger Sequencing
  • 7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

  • 8.1. Introduction
  • 8.2. Organ Transplantation
  • 8.3. Stem Cell Transplantation
  • 8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostic Applications
    • 9.2.1. Antibody Screening
    • 9.2.2. Chimerism Monitoring
  • 9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinical Laboratories & Research Institution
  • 10.3. Hospitals & Transplant Centers
  • 10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
    • 14.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
    • 14.3.3. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
    • 14.3.4. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
    • 14.3.5. BriaCell receives NCI grant for cancer platform development
    • 14.3.6. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
    • 14.3.7. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
    • 14.3.8. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
    • 14.3.9. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 14.3.10. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
    • 14.3.11. Eurobio Scientific acquires GenDx for USD 132.3 million
    • 14.3.12. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension

Companies Mentioned

  • 1. Takara Bio Inc.
  • 2. Chugai Pharmaceutical Co., Ltd.
  • 3. CapitalBio Technology Co., Ltd.
  • 4. Pure MHC, LLC
  • 5. Laboratory Corporation of America Holdings
  • 6. TCR2 Therapeutics by Adaptimmune Therapeutics PLC
  • 7. Bio-Techne Corporation
  • 8. NeoGenomics Laboratories, Inc.
  • 9. Oxford Nanopore Technologies PLC
  • 10. Pure Protein, LLC
  • 11. OraSure Technologies, Inc.
  • 12. CareDx, Inc.
  • 13. DiaSorin S.p.A.
  • 14. BAG Diagnostics GmbH
  • 15. GenDx by Eurobio Scientific Group
  • 16. TBG Diagnostics Ltd.
  • 17. QIAGEN N.V.
  • 18. HEALIOS K.K.
  • 19. Thermo Fisher Scientific, Inc.
  • 20. Merck KGaA
  • 21. Illumina, Inc.
  • 22. BGI Genomics Co.,Ltd.
  • 23. Becton, Dickinson, and Company
  • 24. Hologic, Inc.
  • 25. Bio-Rad Laboratories, Inc.
  • 26. Lonza Group Ltd.
  • 27. STEMCELL Technologies Inc.
  • 28. F. Hoffman-La Roche AG
  • 29. CeGaT GmbH
  • 30. Fujirebio, Inc. by H.U. Group Holdings, Inc.
  • 31. Eurofins Scientific SE
  • 32. Invectys Inc.
  • 33. Creative Biolabs, Inc.
  • 34. ImmunOs Therapeutics AG
  • 35. Immucor, Inc. by Werfen, S.A.
  • 36. Immatics N.V.
  • 37. T-Cure Bioscience Inc.
  • 38. Agilent Technologies, Inc.
  • 39. Garuda Therapeutics

LIST OF FIGURES

  • FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
  • TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR